Recombinant TPO and TPO receptor agonists have been developed for therapeutic use in various clinical settings. These agents are used to treat thrombocytopenia associated with chemotherapy, chronic liver diseases, and bone marrow disorders. TPO receptor agonists mimic the action of endogenous TPO, stimulating platelet production and reducing the need for platelet transfusions.
